- Home
- ESPR vs WLKP Comparison
ESPR vs WLKP Comparison
Compare ESPR & WLKP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESPR
- WLKP
- Stock Information
- Founded
- ESPR 2008
- WLKP 2014
- Country
- ESPR United States
- WLKP United States
- Employees
- ESPR N/A
- WLKP N/A
- Industry
- ESPR Biotechnology: Pharmaceutical Preparations
- WLKP Major Chemicals
- Sector
- ESPR Health Care
- WLKP Industrials
- Exchange
- ESPR Nasdaq
- WLKP Nasdaq
- Market Cap
- ESPR 660.1M
- WLKP 652.0M
- IPO Year
- ESPR 2013
- WLKP 2014
- Fundamental
- Price
- ESPR $3.68
- WLKP $18.74
- Analyst Decision
- ESPR Buy
- WLKP
- Analyst Count
- ESPR 7
- WLKP 0
- Target Price
- ESPR $6.86
- WLKP N/A
- AVG Volume (30 Days)
- ESPR 7.0M
- WLKP 100.2K
- Earning Date
- ESPR 11-06-2025
- WLKP 10-30-2025
- Dividend Yield
- ESPR N/A
- WLKP 10.07%
- EPS Growth
- ESPR N/A
- WLKP N/A
- EPS
- ESPR N/A
- WLKP 1.39
- Revenue
- ESPR $303,802,000.00
- WLKP $1,133,706,000.00
- Revenue This Year
- ESPR $18.83
- WLKP $3.27
- Revenue Next Year
- ESPR N/A
- WLKP $13.98
- P/E Ratio
- ESPR N/A
- WLKP $13.42
- Revenue Growth
- ESPR 2.83
- WLKP N/A
- 52 Week Low
- ESPR $0.69
- WLKP $17.75
- 52 Week High
- ESPR $3.94
- WLKP $25.04
- Technical
- Relative Strength Index (RSI)
- ESPR 71.27
- WLKP 46.84
- Support Level
- ESPR $2.66
- WLKP $17.85
- Resistance Level
- ESPR $3.26
- WLKP $18.99
- Average True Range (ATR)
- ESPR 0.23
- WLKP 0.49
- MACD
- ESPR 0.05
- WLKP 0.09
- Stochastic Oscillator
- ESPR 94.43
- WLKP 70.00
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
About WLKP Westlake Chemical Partners LP Common Units representing limited partner interests
Westlake Chemical Partners LP is a part of the chemical industry in the United States. Its operations are conducted through OpCo, it acquires and develops ethylene production facilities, which convert ethane into ethylene. OpCo sells ethylene and its co-products such as propylene, crude butadiene, pyrolysis gasoline, and hydrogen to Westlake and other customers located in the United States. Its assets include three ethylene production facilities in Calvert City, Kentucky, and Lake Charles, Louisiana.